<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534662</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOMINA</org_study_id>
    <nct_id>NCT02534662</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) for Gastric Reduction</brief_title>
  <official_title>A Prospective Study to Evaluate the Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theodor Bilharz Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theodor Bilharz Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: Study to evaluate safety and feasibility of an endoluminal vertical gastroplasty&#xD;
      (EVG) using an endoluminal-suturing device.&#xD;
&#xD;
      Briefly, Vertical gastric plication is a novel surgical approach for reducing the stomach&#xD;
      capacity. Anterior surface plication and greater curvature plication are variations of&#xD;
      vertical gastric plication that reduce the gastric capacity through infolding of the anterior&#xD;
      surface or greater curvature of the stomach, respectively. These approaches have been tested,&#xD;
      with positive results.&#xD;
&#xD;
      A transoral or endoluminal approach (ie, a procedure that requires no incision, because&#xD;
      access is granted through the mouth) offers the potential for additional benefit to the&#xD;
      patient, because the procedures continue to become more and more minimally invasive.&#xD;
&#xD;
      Advances in endoluminal devices are now allowing clinicians the ability to begin exploring&#xD;
      bariatric procedures performed via flexible endoscopy. Although these procedures may not be&#xD;
      as effective as their surgical counterparts, these less-invasive options may relieve patients&#xD;
      of the significant risks associated with surgery.&#xD;
&#xD;
      Study duration and number of subjects A period of approximately 6 months is anticipated form&#xD;
      the time the time the first patient is enrolled to the completion of the last patient.&#xD;
&#xD;
      The participants will be followed as follow:&#xD;
&#xD;
      Day (0): Procedure Day (+1): Clinical Follow up and discharge (i.e. if no adverse effects&#xD;
      observed)&#xD;
&#xD;
      1 month: Follow up endoscopy, Clinical assessment 3 month: Follow up endoscopy, Clinical&#xD;
      assessment 6 month: Final assessment (Endoscopically and Clinical) On Parallel a nutritional&#xD;
      specialist will monitor the patient on quarterly basis (1,3,6,12).&#xD;
&#xD;
      Study procedures The intervention will be performed under general anesthesia with tracheal&#xD;
      intubation. Endomina will be introduced into the stomach over guide wires and then fixed to&#xD;
      the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior&#xD;
      sutures after argon plasma coagulation of the tissue opposition areas in order to ensure&#xD;
      persistence of the pouch reduction. Patient will be kept overnight after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery is the only effective treatment for morbid obesity and can be divided into&#xD;
      restrictive surgeries (Lap Band and Sleeve gastrectomy), malabsorptive surgeries (Biliary&#xD;
      pancreatic deviation and duodenal switch) or a combination of both (RYGBP).&#xD;
&#xD;
      This later technique is the most common and most effective surgical procedure performed&#xD;
      worldwide and has been processed to be an effective treatment of morbid obesity and its&#xD;
      complications, achieving excess weight loss of 65 to 80 % ; 1-2 years after surgery.1&#xD;
      Vertical gastric plication is a novel surgical approach for reducing the stomach capacity.&#xD;
      Anterior surface plication and greater curvature plication are variations of vertical gastric&#xD;
      plication that reduce the gastric capacity through infolding of the anterior surface or&#xD;
      greater curvature of the stomach, respectively. These approaches have been tested, with&#xD;
      positive results. 3 A transoral or endoluminal approach (ie, a procedure that requires no&#xD;
      incision, because access is granted through the mouth) offers the potential for additional&#xD;
      benefit to the patient, because the procedures continue to become more and more minimally&#xD;
      invasive.&#xD;
&#xD;
      Advances in endoluminal devices are now allowing clinicians the ability to begin exploring&#xD;
      bariatric procedures performed via flexible endoscopy. Although these procedures may not be&#xD;
      as effective as their surgical counterparts, these less-invasive options may relieve patients&#xD;
      of the significant risks associated with surgery. 4&#xD;
&#xD;
      Endomina (Endo Tools Therapeutics, Nivelles, Belgium) is CE mark robot driven device that may&#xD;
      be attached to an endoscope inside the body and allows remote manipulation of the arms of&#xD;
      devices during a peroral intervention. It offers the possibilities of making transoral&#xD;
      surgical full thickness sutures and may allow performing, via a transoral route.&#xD;
&#xD;
      Study design Prospective, non-randomized, open-label, single-center safety and feasibility&#xD;
      study&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Study to evaluate safety and feasibility of an endoluminal vertical gastroplasty (EVG) using&#xD;
      an endoluminal-suturing device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety characterized by the incidence of all Adverse Device Effects (ADEs), physical examination (vital signs), laboratory tests, and subsequent adverse events</measure>
    <time_frame>12 month</time_frame>
    <description>Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.&#xD;
In addition, safety assessments will be determined based on physical examination (vital signs) and laboratory tests during scheduled visits. Safety evaluations will also be performed to ensure no subsequent adverse events have occurred and to ensure any adverse events during the trial that are considered on-going are stable or have resolved. Safety will be assessed at 1 and 6 month following the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility assessment obtained by measurements of total weight loss and excess weight loss</measure>
    <time_frame>12 month</time_frame>
    <description>Information on efficacy will be obtained by measurements of total weight loss and excess weight loss during 6 month with an optional extension at 12 month</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENDOMINA</intervention_name>
    <description>Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21-64 years;&#xD;
&#xD;
          -  BMI &gt; 40 Kg/m2 or BMI &gt;35 Kg/m2 with comorbidities&#xD;
&#xD;
          -  Must be able to comply with all study requirements for the duration of the study as&#xD;
             outlined in the protocol. This includes complying with the visit schedule as well as&#xD;
             study specific procedures such as: clinical assessment , endoscopy, radiography, as&#xD;
             well as laboratory investigations.&#xD;
&#xD;
          -  Must be able to understand and be willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Achalasia and any other esophageal motility disorders&#xD;
&#xD;
          -  Heart diseases: unstable angina, myocardial infarction within the past year, or heart&#xD;
             disease classified within the New York Heart Association's Class III or IV functional&#xD;
             capacity.&#xD;
&#xD;
          -  Hypertension: uncontrolled hypertension during last 3 month&#xD;
&#xD;
          -  Severe renal, hepatic, pulmonary disease or cancer;&#xD;
&#xD;
          -  GIT stenosis or obstruction&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Impending gastric surgery 60 days post intervention;&#xD;
&#xD;
          -  Currently participating in other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Deviere, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Universit√© Libre de Bruxelles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasme Hospital , ULB</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Theodor Bilharz Research Institute</investigator_affiliation>
    <investigator_full_name>Mostafa Ibrahim</investigator_full_name>
    <investigator_title>Gastroenterology and Hepatopancreatology Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

